A novel therapeutic giving cancer patients new hope.

We are focused on rapidly advancing our lead therapeutic candidate, GP-2250, for the treatment of multiple cancer indications including pancreatic and ovarian.

Learn More

Truly novel.
Truly important.

We are on a mission to improve therapeutic outcomes for cancer patients with GP-2250, a tumor-cell selective agent with a truly novel mechanism of action.

Homepage Graphic 1x

Preclinical research with GP-2250 demonstrated significant anti-cancer activity in numerous established and primary cell lines. GP-2250’s novel MOA and degree of preclinical activity is exciting and could be a potentially important addition to the oncologists’ armamentarium to benefit patients.

Prof. Dr. med. Chris Braumann

EvK Gelsenkirchen, University of Duisburg-Essen, Germany

It is so refreshing to work with an organization that not only shares wholeheartedly in our mission to improve survival and quality of life for patients, but has truly unique science that provides new hope in the fight against cancer.

Dr. Anup Kasi, University of Kansas Medical Center

GP-2250 Phase 1/2 Principal Investigator

Our Science

Disrupting cancer cell metabolism.

Our unique, novel, and proprietary mechanism of action targets the primary mechanism of cancer cell energy production to disrupt mitochondrial integrity and bring about cancer cell death.

Video Image

Discover Our Science

Focused on what matters most.

While GP-2250 demonstrates broad potential in preclinical research across cancers and therapeutic applications, we have chosen to first focus on pancreatic cancer—a condition with a clear unmet need. Early clinical experience is promising.

Participate in our ongoing pancreatic cancer study

Early Clinical Results Improve Quality Of Life

The Latest

Publications

Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. MBC Cancer

2017, 17, 1-13. DOI: 10.1CO Annual Meetings 2020, Chicago (Abstract: Journal of Clinical Oncology 38, no. 15_suppl. DOI: 10.1200/JCO.2020.38.15_suppl.e16750
C. Braumann, M. Buchholz, B. Majchrzak – Stiller, S. Hahn, W. Uhl, A. Kasi, T. Mueller.

read more

Pancreatic Tumor Remission in PDX-Models by Treatment with Gemcitabine in Combination with the Oxathiazine GP-2250 promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo. MBC Cancer

German Cancer Congress, February 2020, Berlin, Germany (Abstract: Oncology Res Treat 2020; 43 (supply 1): 1-265, abstract 455, page 58 DOI: 10.1159/000506491)
B. Majchrzak-Stiller, M. Buchholz, S. Hahn, C. Braumann, W. Uhl.

read more

Events

Panavance Leadership Team participation in the Virtual Investor Innovations in Oncology Event


Greg Bosch, Chairman and CEO of Panavance Therapeutics along with other members of the Panavance Leadership Team participated in the Virtual Investor Innovations in Oncology Spotlight Event. As part of the virtual roundtable event, the Company discussed its lead program, GP-2250, a tumor cell selective and broadly active small molecule with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer cell death.

read more